Imunon, Inc.

Imunon, Inc. announced positive preliminary data from its ongoing Phase 2 minimal residual disease (MRD) translational clinical trial of IMNN-001 for advanced ovarian cancer. The data showed a deeper antitumor response with IMNN-001, including lower MRD-positive rates, higher circulating tumor DNA (ctDNA) clearance, and a numerically higher rate of patients achieving no evidence of disease compared to the control arm. These findings, combined with a consistent favorable safety profile, reinforce the potential of IMNN-001 and support its advancement in the pivotal Phase 3 OVATION 3 trial.

Imunon, Inc. announced the retirement of its interim Chief Financial Officer, Jeffrey Church, effective July 1, 2026. Mr. Church will transition to a consulting role to ensure a smooth handover. Concurrently, the company appointed Josh Blacher as the new interim Chief Financial Officer, also effective July 1, 2026. Mr. Blacher, an employee of Danforth Health, Inc., will serve as both principal financial and accounting officer.

Imunon, Inc. announced that its President and CEO, Stacy Lindborg, Ph.D., will present at the Life Sciences Investor Forum on Thursday, June 25, 2026, at 12:00 p.m. ET. The live, interactive online event will allow investors to ask questions in real-time, with one-on-one meetings also available. An archived webcast will be posted on the company's website. Imunon is a clinical-stage biotechnology company with a lead Phase 3 program, IMNN-001, for advanced ovarian cancer, and has completed dosing for its COVID-19 booster vaccine, IMNN-101.

Imunon, Inc. stockholders approved an amendment to the 2018 Stock Incentive Plan, increasing the aggregate number of shares available for awards by an additional 1,000,000, bringing the new total to 1,265,004 shares. Additionally, stockholders elected two Class I directors, ratified the appointment of WithumSmith + Brown, PC as the independent registered public accounting firm for 2026, and approved the 2025 executive compensation on an advisory basis.

Imunon, Inc. has entered into a securities purchase agreement with Streeterville Capital, LLC, securing up to $10 million in financing. The deal comprises $2.5 million in Series A Preferred Stock and $7.72 million in secured promissory notes (Note A-1 for $2.72M and Note B for $5M). The funds will support general corporate purposes, including research and development for its Phase 3 OVATION 3 study. The notes have varying interest rates and maturity dates, with a portion of the funds placed in a collateral account.

Imunon, Inc. announced it has secured $10 million in financing to support the continued enrollment of its pivotal Phase 3 OVATION 3 clinical trial for IMNN-001 in advanced ovarian cancer. The financing package includes $2.5 million from the issuance of preferred stock and $7.72 million from two secured promissory notes. The company highlighted this "investor-friendly" structure as designed to minimize dilution for existing shareholders and strengthen its balance sheet, while also referencing positive updated Phase 2 clinical data for IMNN-001.

Imunon, Inc. reported a net loss of $4.2 million for the first quarter of 2026, an increase from $4.1 million in the prior year. The company's cash and cash equivalents significantly decreased to $4.8 million by March 31, 2026, with $4.0 million used in operating activities during the quarter. Management has identified substantial doubt about the company's ability to continue as a going concern, citing a need for additional capital funding, partnerships, and cost reductions.

Imunon, Inc. reported its first quarter 2026 financial results and provided a business update, highlighting significant progress in its lead candidate, IMNN-001. The final Phase 2 OVATION 2 study data demonstrated a median 14.7-month increase in overall survival for women with newly diagnosed advanced ovarian cancer, with an even greater increase when combined with PARP inhibitors. The company's Phase 3 OVATION 3 trial enrollment is ahead of schedule, and the FDA has aligned with the protocol, confirming a path to BLA filing. Financially, Imunon reported a net loss of $4.3 million for the quarter, an increase from the prior year, primarily due to trial-related expenses for the OVATION 3 study, and held $4.8 million in cash and cash equivalents.

Imunon, Inc. has established change of control agreements with its Chief Executive Officer, Chief Medical Officer, and General Counsel. These agreements, approved by the Compensation Committee, provide severance benefits to these executives if their employment is terminated under specific circumstances related to a change in control of the company. Benefits include a lump sum payment, continued health and life insurance coverage, and full acceleration of equity awards.

Imunon, Inc. announced its Annual Meeting of Stockholders will be held virtually on Tuesday, June 16, 2026, at 10:00 AM Eastern Time. Stockholders will vote on several key proposals, including the election of two Class I Directors, the ratification of WithumSmith+Brown PC as the independent auditor for fiscal year 2026, an advisory vote on 2025 executive compensation, and an amendment to the 2018 Stock Incentive Plan to increase the aggregate number of shares available for awards. The record date for voting is April 17, 2026, with 3,983,342 shares outstanding.